UK PETROCHEMICAL INDUSTRY BRACES FOR VARIOUS BREXIT SCENARIOS

November 10, 2018

More than two years after the Brexit vote and less than four months before the UK is set to leave the European Union, one word is continuously being used when referring to postBrexit Britain – uncertainty. The lack of clarity over Brexit has weighed on the value of the pound sterling and confusion on long-term trade agreements has made it difficult for businesses of all sorts to plan firm strategies beyond 29 March 2019. The petrochemical industry is no exception given that the EU is its most important trading partner for chemicals, accounting for 60% of UK chemical industry exports and 75% of imports. British companies are currently bracing themselves for the various scenarios likely to unfold in the final months before the UK officially breaks away from the EU.

Spotlight

Melinta Therapeutics

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta’s lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

OTHER WHITEPAPERS
news image

THE INTELLIGENT ENTERPRISE FOR THE CHEMICAL INDUSTRY

whitePaper | January 14, 2023

As industries reexamine their partners and processes in a critical search for efficiency, chemical businesses are feeling increasing cost and margin pressure. Still, the companies that can adapt new models and automate their processes have an unprecedented opportunity to have an outsized positive impact.

Read More
news image

A GREEN ALTERNATIVE TO TRADITIONAL PLASTICS

whitePaper | July 6, 2022

Plastics are found in a wide variety of products, ranging from grocery bags to car bumpers and are composed predominantly of synthetic polymers derived from petroleum.

Read More
news image

WHAT NEXT FOR THE CHEMICAL INDUSTRY?

whitePaper | September 22, 2022

Chemical companies today are experiencing unexpected economic scenarios. This has required them to adapt to rapidly changing supply & demand and adjust workplace structures to ensure the health & safety of their workers.

Read More
news image

Specialty Chemicals Manufacturers Can Recoup Investor ROI via Automated Process Flows

whitePaper | November 25, 2022

In specialty chemicals, R&D teams have long struggled to deliver the results investors expect.

Read More
news image

Silicone-Base Coating Mitigates Corrosion Under Insulation (CUI) In Petrochemical Plants

whitePaper | June 15, 2021

Corrosion under insulation (CUI) is one of the costliest problems in the petrochemical industry. It also presents a high degree of potential danger. CUI occurs when moisture mixed with contaminants infiltrates insulation, encouraging the development of corrosion cells on the steel underneath. This paper demonstrates how Sherwin-Williams Heat-Flex® High-Temp 1200 withstands temperature fluctuations, thermal shock and other upset conditions to protect against hidden CUI.

Read More
news image

2023 chemical industry outlook

whitePaper | September 22, 2022

As the US chemical industry transforms itself by adjusting portfolios, retooling supply chains, and advancing material innovation, 2023 will set the stage for a reset in terms of materials transformation.

Read More

Spotlight

Melinta Therapeutics

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta’s lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

Events